Haemophilus influenzae vaccines

Vaccines

Volumn , Issue , 2008, Pages 157-176

  Chandran, Aruna ^a   Watt, James P ^a   Santosham, Mathuram ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890534302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50015-5     Document Type: Chapter

References (338)

1. World Health Organization Haemophilus influenzae Type b (Hib): Fact Sheet. Online. Available at: http://www.who.int/mediacentre/factsheets/fs294/en/ December 2005.
2. Haemophilus influenzae Type b (Hib): Conclusions and Recommendations from the Immunization Strategic Advisory Group. Weekly Epidemiologic Record 81(1), 1-12.
3. R Koch (1883) Bericht uber die Thatigkeit der deutschen Cholera-kommission in Aegpytten and Ostindien. Wien Med Wochenschr 53 1548-1551.
4. R Pfieffer (1893) Die Aetiologie der Influenzaa. Z Hyg Infect 13 357-386.
5. E Tognotti (2003) Scientific triumphalism and learning from facts: bacteriology and the ‘Spanish flu’ challenge of 1918. Soc Hist Med 16(1), 97-110.
6. M Pittman (1931) Variation and type specificity in the bacterial species Haemophilus influenzae. J Exp Med 53 471-493.
7. JD Wenger, R Pierce, K Deaver, et al. (1992) Invasive Haemophilus influenzae disease: a population-based evaluation of the role of capsular polysaccharide serotype. Haemophilus Influenzae Study Group. J Infect Dis 165(Suppl 1), S34–S35.
8. JW St Geme III (1994) Early events in the pathogenesis of Haemophilus influenzae disease. VL Miller, JB Kaper, DA Portnoy, RR Isberg (Eds) Molecular Genetics of Bacterial Pathogenesis Washington, DC: American Society for Microbiology 157-172.
9. TF Murphy (2005) Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges. Expert Rev Vaccines 4(6), 843-853.
10. JW Geme St and S Falkow III (1991) Loss of capsule expression by Haemophilus influenzae type b results in enhanced adherence to and invasion of human cells. Infect Immun 59(4), 1325-1333.
11. L van Alphen (1994) Molecular Epidemiology of Hib Strains. RW Ellis, D Granoff (Eds) Development and Clinical Uses of Haemophilus b Conjugate Vaccines New York, NY: Marcel Dekker 129-144.
12. LD Fothergill and J Wright (1933) Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 24 273.
13. H Kayhty, H Makela and H Peltola (1994) Immunological basis for PRP vaccines. RW Ellis, DM Granoff (Eds) Development and Clinical Uses of Haemophilus b Conjugate Vaccines New York, NY: Marcel Dekker 1-18.
14. H Peltola (2000) Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13(2), 302-317.
15. JP Watt, OS Levine and M Santosham (2003) Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22–25, 2002. J Pediatr 143(6 Suppl), S163-S187.
16. GM Tebbutt (1983) Evaluation of some methods for the laboratory identification of Haemophilus influenzae. J Clin Pathol 36(9), 991-995.
17. AJ Swift, ER Moxon, A Zwahlen and JA Winkelstein (1991) Complement-mediated serum activities against genetically defined capsular transformants of Haemophilus influenzae. Microb Pathog 10(4), 261-269.
18. AA Lindberg (1999) Polyosides (encapsulated bacteria). C R Acad Sci III 322(11), 925-932.
19. ER Moxon and KA Vaughn (1981) The type b capsular polysaccharide as a virulence determinant of Haemophilus influenzae: studies using clinical isolates and laboratory transformants. J Infect Dis 143(4), 517-524.
20. ER Moxon and JS Kroll (1990) The role of bacterial polysaccharide capsules as virulence factors. Curr Top Microbiol Immunol 150 65-85.
21. DF Kelly, ER Moxon and AJ Pollard (2004) Haemophilus influenzae type b conjugate vaccines. Immunology 113(2), 163-174.
22. M Roberts, TL Stull and AL Smith (1981) Comparative virulence of Haemophilus influenzae with a type b or type d capsule. Infect Immun 32(2), 518-524.
23. RM Crisel, RS Baker and DE Dorman (1975) Capsular polymer of Haemophilus influenzae type b. Structural characterization of the capsular polymer of strain Eagan. J Biol Chem 250 4926.
24. A Zwahlen, JS Kroll, LG Rubin and ER Moxon (1989) The molecular basis of pathogenicity in Haemophilus influenzae: comparative virulence of genetically-related capsular transformants and correlation with changes at the capsulation locus cap. Microb Pathog 7(3), 225-235.
25. JS Kroll and R Booy (1996) Haemophilus influenzae: capsule vaccine and capsulation genetics. Mol Med Today 2(4), 160-165.
26. JS Kroll and PR Langford (1994) Molecular Aspects of the Pathogenesis of Invasive Haemophilus influenzae Type b Infections. RW Ellis, DM Granoff (Eds) Development and Clinical Uses of Haemophilus b Conjugate Vaccines New York, NY: Marcel Dekker 145-177.
27. JS Kroll and ER Moxon (1988) Capsulation and gene copy number at the cap locus of Haemophilus influenzae type b. J Bacteriol 170(2), 859-864.
28. GJ Noel, A Brittingham, AA Grenado and DM Mosser (1996) Effect of amplification of the cap b locus on complement-mediated bacteriolysis and opsonization of type b Haemophilus influenzae. Infect Immun 64 4769-4775.
29. C Ogilvie, A Omikunle, Y Wang, et al. (2001) Capsulation loci of non-serotype b encapsulated Haemophilus influenzae. J Infect Dis 184(2), 144-149.
30. BG Kapogiannis, S Satola, HL Keyserling and MM Farley (2005) Invasive infections with Haemophilus influenzae serotype a containing an IS1016- bexA partial deletion: possible association with virulence. Clin Infect Dis 41(11), e97-e103.
31. GP Jarosik and EJ Hansen (1994) Identification of a new locus involved in expression of Haemophilus influenzae type b lipooligosaccharide. Infect Immun 62(11), 4861-4867.
32. AP Johnson and TJ Inzana (1986) Loss of ciliary activity in organ cultures of rat trachea treated with lipo-oligosaccharide from Haemophilus influenzae. J Med Microbiol 22(3), 265-268.
33. AE Williams, DJ Maskell and ER Moxon (1991) Relationship between intracellular survival in macrophages and virulence of Haemophilus influenzae type b. J Infect Dis 163(6), 1366-1369.
34. NG Guerina, S Langermann, HW Clegg, et al. (1982) Adherence of piliated Haemophilus influenzae type b to human oropharyngeal cells. J Infect Dis 146(4), 564.
35. WF Goebel and OT Avery (1931) Chemo-immunological studies on conjugated carbohydrate-protein, V. The immunological specificty of an antigen prepared by combining one capsular polysaccharide of type 3 pneumococcus with foreign protein. J Exptl Med 54 437.
36. MM Farley, DS Stephens, SL Kaplan and EO Mason Jr (1990) Pilus- and non-pilus-mediated interactions of Haemophilus influenzae type b with human erythrocytes and human nasopharyngeal mucosa. J Infect Dis 161(2), 274-280.
37. SL Kaplan, EO Mason Jr and BL Wiedermann (1983) Role of adherence in the pathogenesis of Haemophilus influenzae type b infection in infant rats. Infect Immun 42(2), 612-617.
38. H Kayhty, V Karanko, H Peltola and PH Makela (1984) Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 74(5), 857-865.
39. H Kayhty, H Peltola, V Karanko and PH Makela (1983) The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147(6), 1100.
40. P Anderson (1984) The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 149(6), 1034-1035.
41. RS Daum and DM Granoff (1994) Lessons Learned from the Evaluation of Immunogenicity. RW Ellis, D Granoff (Eds) Development and Clinical Uses of Haemophilus b Conjugate Vaccines New York, NY: Marcel Dekker 291-312.
42. M Santosham (1993) Prevention of Haemophilus influenzae type b disease. Vaccine 11(Suppl 1), S52–S57.
43. TV Murphy, D Granoff, DF Chrane, et al. (1985) Pharyngeal colonization with Haemophilus influenzae type b in children in a day care center without invasive disease. J Pediatr 106(5), 712-716.
44. ML Barbour (1996) Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg Infect Dis 2(3), 176-182.
45. RH Michaels, CS Poziviak, FE Stonebraker and CW Norden (1976) Factors affecting pharyngeal Haemophilus influenzae type b colonization rates in children. J Clin Microbiol 4(5), 413-417.
46. AK Takala, J Eskola, M Leinonen, et al. (1991) Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 164(5), 982-986.
47. AK Takala, M Santosham, J meido-Hill, et al. (1993) Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children. Pediatr Infect Dis J 12(7), 593-599.
48. RA Adegbola, O Secka, G Lahai, et al. (2005) Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 366(9480), 144-150.
49. H Kayhty (1994) Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 22(4), 397-402.
50. JL Coulehan, RH Michaels, C Hallowell, et al. (1984) Epidemiology of Haemophilus influenzae type B disease among Navajo Indians. Public Health Rep 99(4), 404-409.
51. GA Losonsky, M Santosham, VM Sehgal, et al. (1984) Haemophilus influenzae disease in the White Mountain Apaches: molecular epidemiology of a high risk population. Pediatr Infect Dis 3(6), 539-547.
52. A Jain, P Kumar and S Awasthi (2005) High nasopharyngeal carriage of drug resistant Streptococcus pneumoniae and Haemophilus influenzae in North Indian schoolchildren. Trop Med Int Health 10(3), 234-239.
53. SJ Olsen, S Dejsirilert, L Sangsuk, et al. (2005) Frequent Haemophilus influenzae type B colonization in rural Thailand. Pediatr Infect Dis J 24(8), 739-742.
54. RY Sung, JM Ling, SM Fung, et al. (1995) Carriage of Haemophilus influenzae and Streptococcus pneumoniae in healthy Chinese and Vietnamese children in Hong Kong. Acta Paediatr 84(11), 1262-1267.
55. ER Moxon (1986) The carrier state: Haemophilus influenzae. J Antimicrob Chemother 18(Suppl A), 17-24.
56. K Galil, R Singleton, OS Levine, et al. (1999) Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 179(1), 101-106.
57. AK Takala, O Meurman, M Kleemola, et al. (1993) Preceding respiratory infection predisposing for primary and secondary invasive Haemophilus influenzae type b disease. Pediatr Infect Dis J 12(3), 189-195.
58. MW Raza, MM Ogilvie, CC Blackwell, et al. (1993) Effect of respiratory syncytial virus infection on binding of Neisseria meningitidis and Haemophilus influenzae type b to a human epithelial cell line (HEp-2). Epidemiol Infect 110(2), 339-347.
59. RL Myerowitz and RH Michaels (1981) Mechanism of potentiation of experimental Haemophilus influenzae type B disease in infant rats by influenza A virus. Lab Invest 44(5), 434-441.
60. V Avadhanula, CA Rodriguez, JP Devincenzo, et al. (2006) Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. J Virol 80(4), 1629-1636.
61. JP Nuorti, JC Butler, MM Farley, et al. (2000) Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 342(10), 681-689.
62. KA Cartwright, DM Jones, AJ Smith, et al. (1991) Influenza A and meningococcal disease. Lancet 338(8766), 554-557.
63. LG Rubin, A Zwahlen and ER Moxon (1985) Role of intravascular replication in the pathogenesis of experimental bacteremia due to Haemophilus influenzae type b. J Infect Dis 152(2), 307-314.
64. DW Scheifele, RS Daum, VP Syriopoulou, et al. (1980) Haemophilus influenzae bacteremia and meningitis in infant primates. J Lab Clin Med 95(3), 450-462.
65. L La Scolea Jr, SV Rosales, RC Welliver and PL Ogra (1985) Mechanisms underlying the development of meningitis or epiglottitis in children after Haemophilus influenzae type b bacteremia. J Infect Dis 151(6), 1162-1165.
66. M Santosham and ER Moxon (1977) Detection and quantitation of bacteremia in childhood. J Pediatr 91(5), 719-721.
67. ME Kilpatrick, IA Mikhail and NI Girgis (1987) Negative cultures of cerebrospinal fluid in partially treated bacterial meningitis. Trop Geogr Med 39(4), 345-349.
68. P Radstrom, A Backman, N Qian, et al. (1994) Detection of bacterial DNA in cerebrospinal fluid by an assay for simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and streptococci using a seminested PCR strategy. J Clin Microbiol 32(11), 2738-2744.
69. SC Singhi, D Mohankumar, PD Singhi, et al. (2002) Evaluation of polymerase chain reaction (PCR) for diagnosing Haemophilus influenzae b meningitis. Ann Trop Paediatr 22(4), 347-353.
70. RJ van Ketel and AL van de WB (1990) Detection of Haemophilus influenzae in cerebrospinal fluids by polymerase chain reaction DNA amplification. J Med Microbiol 33(4), 271-276.
71. DJ Hoban, E Witwicki and GW Hammond (1985) Bacterial antigen detection in cerebrospinal fluid of patients with meningitis. Diagn Microbiol Infect Dis 3(5), 373-379.
72. MR Shivaprakash, V Rajagopal and S Nagarathna (2004) Latex agglutination test in the diagnosis of pyogenic meningitis. J Commun Dis 36(2), 127-131.
73. GW Ajello, GA Bolan, PS Hayes, et al. (1987) Commercial latex agglutination tests for detection of Haemophilus influenzae type b and Streptococcus pneumoniae antigens in patients with bacteremic pneumonia. J Clin Microbiol 25(8), 1388-1391.
74. CS Witt, JM Montgomery, W Pomat, et al. (1990) Detection of Streptococcus pneumoniae and Haemophilus influenzae type b antigens in the serum and urine of patients with pneumonia in Papua New Guinea: comparison of latex agglutination and counterimmunoelectrophoresis. Rev Infect Dis 12(Suppl 8), S1001–S1005.
75. MJ Manary, D Lehmann, A Michael, et al. (1993) Antigenuria in healthy Papua New Guinean children with nasal Haemophilus influenzae type b carriage. Ann Trop Paediatr 13(4), 385-389.
76. LG Rubin and L Carmody (1987) Pneumococcal and Haemophilus influenzae type b antigen detection in children at risk for occult bacteremia. Pediatrics 80(1), 92-96.
77. TL Ballard, MH Roe, RC Wheeler, et al. (1987) Comparison of three latex agglutination kits and counterimmunoelectrophoresis for the detection of bacterial antigens in a pediatric population. Pediatr Infect Dis J 6(7), 630-634.
78. GW Counts and M Turck (1977) Screening for cross-reacting capsular polysaccharide K antigens of Escherichia coli using antiserum agar. J Clin Microbiol 5(4), 490-491.
79. EP Rothstein, DV Madore, JA Girone, et al. (1991) Comparison of antigenuria after immunization with three Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J 10(4), 311-314.
80. JG Goepp, M Hohenboken, J meido-Hill and M Santosham (1992) Persistent urinary antigen excretion in infants vaccinated with Haemophilus influenzae type b capsular polysaccharide conjugated with outer membrane protein from Neisseria meningitidis. Pediatr Infect Dis J 11(1), 2-5.
81. RA Adegbola, A Leach, K Mulholland, et al. (1998) Antigenuria in Gambian infants following immunization with a Haemophilus influenzae type b polyribosylribitol phosphate-tetanus toxoid protein conjugate (PRP-T) vaccine. Diagn Microbiol Infect Dis 32(1), 15-19.
82. AS Dajani, BI Asmar and MC Thirumoorthi (1979) Systemic Haemophilus influenzae disease: an overview. J Pediatr 94(3), 355-364.
83. P Karma, J Luotonen, J Pukander, et al. (1983) Haemophilus influenzae in acute otitis media. Acta Otolaryngol 95(1–2), 105-110.
84. AB Anderson, DM Ambrosino and GR Siber (1987) Haemophilus influenzae type b unsuspected bacteremia. Pediatr Emerg Care 3(2), 82-85.
85. AK Takala, J Eskola, J Palmgren, et al. (1989) Risk factors of invasive Haemophilus influenzae type b disease among children in Finland. J Pediatr 115(5 Pt 1), 694-701.
86. RP Rennie and KH Ibrahim (2005) Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin Infect Dis 41(Suppl 4), S234-S238.
87. I Brook, PA Foote and JN Hausfeld (2005) Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid. Int J Antimicrob Agents 26(5), 416-419.
88. GT Simpson, TI McGill and GB Healy (1981) Hemophilus influenzae type b soft tissue infections of the head and neck. Laryngoscope 91(1), 17-29.
89. ED Shapiro, ER Wald and BA Brozanski (1982) Periorbital cellulitis and paranasal sinusitis: a reappraisal. Pediatr Infect Dis 1(2), 91-94.
90. E Vuori-Holopainen and H Peltola (2001) Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. Clin Infect Dis 32(5), 715-726.
91. D Isaacs (1989) Problems in determining the etiology of community-acquired childhood pneumonia. Pediatr Infect Dis J 8(3), 143-148.
92. VS Baselski and RG Wunderink (1994) Bronchoscopic diagnosis of pneumonia. Clin Microbiol Rev 7(4), 533-558.
93. BD Gessner, A Sutanto, M Steinhoff, et al. (1998) A population-based survey of Haemophilus influenzae type b nasopharyngeal carriage prevalence in Lombok Island, Indonesia. Pediatr Infect Dis J 17(9 Suppl), S179-S182.
94. K Mulholland, S Hilton, R Adegbola, et al. (1997) Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 349(9060), 1191-1197.
95. OS Levine, R Lagos, A Munoz, et al. (1999) Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 18(12), 1060-1064.
96. Public Health Sciences Division IB (2004) An Effectiveness Trial of Hib Vaccine in Bangladesh. Health and Science Bulletin 2(3), 11-13.
97. AL de Andrade, JG de Andrade, CM Martelli, et al. (2004) Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. Int J Epidemiol 33(1), 173-181.
98. F de la Hoz, AB Higuera, JL Di Fabio, et al. (2004) Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia. Vaccine 23(1), 36-42.
99. AL Smith, JE Hass, MC Roberts, et al. (1985) Mechanisms of Haemophilus influenzae type b meningitis. MA Sande, AL Smith, RK Root (Eds) Bacterial Meningitis New York, NY: Churchill Livingstone 11.
100. CT D'Angio, RG Froehlke, GA Plank, et al. (1995) Long-term outcome of Haemophilus influenzae meningitis in Navajo Indian children. Arch Pediatr Adolesc Med 149(9), 1001-1008.
101. HG Taylor, RH Michaels, PM Mazur and CB Liden (1984) Intellectual, neuropsychological and achievement outcomes in children six to eight years after recovery from H. influenzae meningitis. Pediatrics 74 198-205.
102. JD Wenger (1998) Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J 17(9 Suppl), S132-S136.
103. HA Bijlmer (1991) World-wide epidemiology of Haemophilus influenzae meningitis; industrialized versus non-industrialized countries. Vaccine 9(Suppl), S5–S9.
104. MR Limcangco, EG Salole and CL Armour (2000) Epidemiology of Haemophilus influenzae type b meningitis in Manila, Philippines, 1994 to 1996. Pediatr Infect Dis J 19(1), 7-11.
105. IH Hussain, A Sofiah, LC Ong, et al. (1998) Haemophilus influenzae meningitis in Malaysia. Pediatr Infect Dis J 17(9 Suppl), S189-S190.
106. R Mahmoud, M Mahmoud, P Badrinath, et al. (2002) Pattern of meningitis in Al-Ain medical district, United Arab Emirates–a decadal experience (1990–99). J Infect 44(1), 22-25.
107. BD Gessner, A Sutanto, M Linehan, et al. (2005) Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 365(9453), 43-52.
108. A Kessler, RF Wetmore and RR Marsh (1993) Childhood epiglottitis in recent years. Int J Pediatr Otorhinolaryngol 25(1–3), 155-162.
109. J McVernon, MP Slack and ME Ramsay (2005) Changes in the epidemiology of epiglottitis following introduction of Haemophilus influenzae type b (Hib) conjugate vaccines in England: a comparison of two data sources. Epidemiol Infect 134(3), 1-3.
110. O Garpenholt, S Hugosson, H Fredlund, et al. (1999) Epiglottitis in Sweden before and after introduction of vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 18(6), 490-493.
111. J Hanna (1992) The epidemiology and prevention of Haemophilus influenzae infections in Australian aboriginal children. J Paediatr Child Health 28(5), 354-361.
112. JI Ward, MK Lum, DB Hall, et al. (1986) Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial. J Infect Dis 153(1), 17-26.
113. C Ferreccio, E Ortiz, L Astroza, et al. (1990) A population-based retrospective assessment of the disease burden resulting from invasive Haemophilus influenzae in infants and young children in Santiago, Chile. Pediatr Infect Dis J 9(7), 488-494.
114. CL Wang, SM Wang, YJ Yang, et al. (2003) Septic arthritis in children: relationship of causative pathogens, complications, and outcome. J Microbiol Immunol Infect 36(1), 41-46.
115. ED Goergens, A McEvoy, M Watson and IR Barrett (2005) Acute osteomyelitis and septic arthritis in children. J Paediatr Child Health 41(1–2), 59-62.
116. SL Kaplan (1994) Pathogenesis and treatment of infants and children. RW Ellis, DM Granoff (Eds) Development and clinical uses of Haemophilus b conjugate vaccines New York, NY: Marcel Dekker 371-388.
117. AW Howard, D Viskontas and C Sabbagh (1999) Reduction in osteomyelitis and septic arthritis related to Haemophilus influenzae type B vaccination. J Pediatr Orthop 19(6), 705-709.
118. BK Ambati, J Ambati, N Azar, et al. (2000) Periorbital and orbital cellulitis before and after the advent of Haemophilus influenzae type B vaccination. Ophthalmology 107(8), 1450-1453.
119. TF Smith, D O'Day and PF Wright (1978) Clinical implications of preseptal (periorbital) cellulitis in childhood. Pediatrics 62(6), 1006-1009.
120. GR Schwartz and SW Wright (1996) Changing bacteriology of periorbital cellulitis. Ann Emerg Med 28(6), 617-620.
121. RG Fisher and DK Benjamin Jr (2002) Facial cellulitis in childhood: a changing spectrum. South Med J 95(7), 672-674.
122. From the Centers for Disease Control and Prevention (2002) Progress toward eliminating Haemophilus influenzae type b disease among infants and children–United States, 1998–2000. MMWR Morb Mortal Wkly Rep 51(11), 234-237.
123. TF Murphy, AL Brauer, AT Schiffmacher and S Sethi (2004) Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170(3), 266-272.
124. JM O'Neill, GJ St III, D Cutter, et al. (2003) Invasive disase due to nontypeable Haemophilus influenzae among children in Arkansas. J Clin Microbiol 41(7), 3064-3069.
125. H Faden, L Duffy, A Williams, et al. (1995) Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life. J Infect Dis 172(132), 135.
126. JO Klein (1997) Role of nontypeable Haemophilus influenzae in pediatric respiratory tract infections. Pediatr Infect Dis J 16(2 Suppl), S5-S8.
127. TJ Falla, SR Dobson, DW Crook, et al. (1993) Population-based study of non-typable Haemophilus influenzae invasive disease in children and neonates. Lancet 341(8849), 851-854.
128. H Faden (1991) Meningitis caused by nontypeable Haemophilus influenzae in a four-month-old infant. Pediatr Infect Dis J 10 254-255.
129. American Academy of Pediatrics (2003) Haemophilus influenzae Infections. LK Pickering (Eds) 2003 Red Book: Report of the Committee on Infectious Diseases Elk Grove Village, IL: American Academy of Pediatrics 293-301.
130. Fever World Health Organization (Ed.) (2005) Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Illnesses with Limited Resources Geneva: WHO Press 133-172.
131. JI Ward, G Gorman, C Phillips and DW Fraser (1978) Hemophilus influenzae type b disease in a day-care center. Report of an outbreak. J Pediatr 92(5), 713-771.
132. CM Ginsburg, GH McCracken Jr, S Rae and JC Parke Jr (1977) Haemophilus influenzae type b disease. Incidence in a day-care center. JAMA 238(7), 604-607.
133. R.I. Andersson vRI, L Gotherfors, S Schmeisser, et al. (1990) Outbreak of Haemophilus influenzae type b meningitis in a day care center. Pediatr Infect Dis J 9(5), 326-332.
134. S Makintubee, GR Istre and JI Ward (1987) Transmission of invasive Haemophilus influenzae type b disease in day care settings. J Pediatr 111(2), 180-186.
135. J Eskola, A Takala, H Kayhty, et al. (1987) Secondary cases of invasive disease caused by spread of Haemophilus influenzae type b. J Infect 14(3), 233-236.
136. JI Ward, DW Fraser, LJ Baraff and BD Plikaytis (1979) Haemophilus influenzae meningitis. A national study of secondary spread in household contacts. N Engl J Med 301(3), 122-126.
137. RH Michaels and CW Norden (1977) Pharyngeal colonization with Haemophilus influenzae type b: a longitudinal study of families with a child with meningitis or epiglottitis due to H. influenzae type b. J Infect Dis 136(2), 222-228.
138. JZ Jordens and MP Slack (1995) Haemophilus influenzae: then and now. Eur J Clin Microbiol Infect Dis 14(11), 935-948.
139. ME Jones, JA Karlowsky, R Blosser-Middleton, et al. (2002) Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int J Antimicrob Agents 19(2), 119-123.
140. SO Sow, S Diallo, JD Campbell, et al. (2005) Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J 24(6), 533-537.
141. YH Kwak, HS Jung, SE Park, et al. (2000) Serotypes and antimicrobial susceptibility in clinical isolates of Haemophilus influenzae from Korean children in prevaccination era. J Korean Med Sci 15(6), 616-622.
142. J Campos, M Hernando, F Roman, et al. (2004) Analysis of invasive Haemophilus influenzae infections after extensive vaccination against H. influenzae type b. J Clin Microbiol 42(2), 524-529.
143. JA Scott, S Mwarumba, C Ngetsa, et al. (2005) Progressive increase in antimicrobial resistance among invasive isolates of Haemophilus influenzae obtained from children admitted to a hospital in Kilifi, Kenya, from 1994 to 2002. Antimicrob Agents Chemother 49(7), 3021-3024.
144. AL de Andrade, MC Brandileone, JL Di Fabio, et al. (2001) Haemophilus influenzae resistance in Latin America: systematic review of surveillance data. Microb Drug Resist 7(4), 403-411.
145. RC Zanella, ST Casagrande, S Bokermann, et al. (2002) Characterization of Haemophilus influenzae isolated from invasive disease in Brazil from 1990 to 1999. Microb Drug Resist 8(1), 67-72.
146. SK Saha, AH Baqui, GL Darmstadt, et al. (2005) Invasive Haemophilus influenzae type B diseases in Bangladesh, with increased resistance to antibiotics. J Pediatr 146(2), 227-233.
147. WG Adams, KA Deaver, SL Cochi, et al. (1993) Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 269(2), 221-226.
148. KM Bisgard, A Kao, J Leake, et al. (1998) Haemophilus influenzae invasive disease in the United States, 1994–1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 4(2), 229-237.
149. TV Murphy, MT Osterholm, LM Pierson, et al. (1987) Prospective surveillance of Haemophilus influenzae type b disease in Dallas County, Texas, and in Minnesota. Pediatrics 79(2), 173-180.
150. SL Cochi, CV Broome and AW Hightower (1985) Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine. A cost-effectiveness model of strategy assessment. JAMA 253(4), 521-529.
151. P Reinert, A Liwartowski, H Dabernat, et al. (1993) Epidemiology of Haemophilus influenzae type b disease in France. Vaccine 11(Suppl 1), S38-S42.
152. H Peltola, H Kayhty, M Virtanen and PH Makela (1984) Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 310(24), 1561-1566.
153. GC Yost, AM Kaplan, R Bustamante, et al. (1986) Bacterial meningitis in Arizona American Indian children. Am J Dis Child 140(9), 943-946.
154. JI Ward, HS Margolis, MK Lum, et al. (1981) Haemophilus influenzae disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease. Lancet 1(8233), 1281-1285.
155. GL Gilbert (1991) Epidemiology of Haemophilus influenzae type b disease in Australia and New Zealand. Vaccine 9(Suppl), S10-S13.
156. M Cadoz, F Denis and ID Mar (1981) [An epidemiological study of purulent meningitis cases admitted to hospital in Dakar, 1970–1979]. Bull World Health Organ 59(4), 575-584.
157. G Campagne, A Garba, A Schuchat, et al. (1998) Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. Am J Trop Med Hyg 59(5), 837-842.
158. FM Russell, JR Carapetis, O Mansoor, et al. (2003) High incidence of Haemophilus influenzae type b infection in children in Pacific island countries. Clin Infect Dis 37(12), 1593-1599.
159. M Zaki, AS Daoud, Q ElSaleh and PW West (1990) Childhood bacterial meningitis in Kuwait. J Trop Med Hyg 93(1), 7-11.
160. YY Al-Mazrou, MH Al-Jeffri, SH Al-Haggar, et al. (2004) Haemophilus type B meningitis in Saudi children under 5 years old. J Trop Pediatr 50(3), 131-136.
161. Review panel on Haemophilus influenzae type b (Hib) disease burden in Bangladesh, Indonesia and other Asian countries, Bangkok, 28–29 January 2004. Wkly Epidemiol Rec 79(18), 173-175.
162. YL Lau, R Yung, L Low, et al. (1998) Haemophilus influenzae type b infections in Hong Kong. Pediatr Infect Dis J 17(9 Suppl), S165-S169.
163. S Rerks-Ngarm, SC Treleaven, S Chunsuttiwat, et al. (2004) Prospective population-based incidence of Haemophilus influenzae type b meningitis in Thailand. Vaccine 22(8), 975-983.
164. Mendsaikhan J, Watt JP, Mansoor O, et al. Childhood Bacterial Meningitis in Ulanbaatar, Mongolia, 2002–2003 [abstract]. In: 4th World Congress of the World Society for Pediatric Infectious Diseases; 2005 September 1–4; Warsaw, Poland.
165. H Peltola (1998) Haemophilus influenzae type b disease and vaccination in Europe: lessons learned. Pediatr Infect Dis J 17(9 Suppl), S126-S132.
166. RA Adegbola, EK Mulholland, O Secka, et al. (1998) Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 177(6), 1758-1761.
167. DW Fraser, CC Geil and RA Feldman (1974) Bacterial meningitis in Bernalillo County, New Mexico: a comparison with three other American populations. Am J Epidemiol 100(1), 29-34.
168. CM Vadheim, DP Greenberg, N Bordenave, et al. (1992) Risk factors for invasive Haemophilus influenzae type b in Los Angeles County children 18–60 months of age. Am J Epidemiol 136(2), 221-235.
169. JC Parke Jr, R Schneerson and JB Robbins (1972) The attack rate, age incidence, racial distribution, and case fatality rate of Haemophilus influenzae type b meningitis in Mecklenbury County, North Carolina. J Pediatr 81(4), 765-769.
170. SL Cochi, DW Fleming, AW Hightower, et al. (1986) Primary invasive Haemophilus influenzae type b disease: a population-based assessment of risk factors. J Pediatr 108(6), 887-896.
171. DM Granoff, T McKinney, EG Boies, et al. (1986) Haemophilus influenzae type b disease in an Amish population: studies of the effects of genetic factors, immunization, and rifampin prophylaxis on the course of an outbreak. Pediatrics 77(3), 289-295.
172. EA Goddard, DW Beatty and EB Hoffman (1996) Immunoglobulin allotypes and genetic susceptibility to invasive Haemophilus influenzae type b and Staphylococcus aureus infections in South African children. Pediatr Infect Dis J 15(5), 419-424.
173. GM Petersen, DR Silimperi, JI Rotter, et al. (1987) Genetic factors in Haemophilus influenzae type b disease susceptibility and antibody acquisition. J Pediatr 110(2), 228-233.
174. RF Floyd, CF Federspiel and W Schaffner (1974) Bacterial meningitis in urban and rural Tennessee. Am J Epidemiol 99(6), 395-407.
175. A Zielinski, CB Kwon, J Tomaszunas-Blaszczyk, et al. (2003) Risk of Haemophilus influenzae type b meningitis in Polish children varies directly with number of siblings: possible implications for vaccination strategies. Eur J Epidemiol 18(9), 917-922.
176. GM Petersen, DR Silimperi, CY Chiu and JI Ward (1991) Effects of age, breast feeding, and household structure on Haemophilus influenzae type b disease risk and antibody acquisition in Alaskan Eskimos. Am J Epidemiol 134(10), 1212-1221.
177. DA Clements, KA Weigle and GL Gilbert (1995) A case-control study examining risk factors for invasive Haemophilus influenzae type b disease in Victoria, Australia 1988–90. J Paediatr Child Health 31(6), 513-518.
178. C Arnold, S Makintube and GR Istre (1993) Day care attendance and other risk factors for invasive Haemophilus influenzae type b disease. Am J Epidemiol 138(5), 333-340.
179. HS Jafari, WG Adams, KA Robinson, et al. (1999) Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus Influenzae Study Group. Am J Public Health 89(3), 364-368.
180. DA Clements, IA Guise, SJ MacInnes and GL Gilbert (1992) Haemophilus influenzae type b infections in Victoria, Australia, 1985–1989. J Infect Dis 165(Suppl 1), S33-S34.
181. GR Istre, JS Conner, CV Broome, et al. (1985) Risk factors for primary invasive Haemophilus influenzae disease: increased risk from day care attendance and school-aged household members. J Pediatr 106(2), 190-195.
182. TV Murphy, JF Clements, M Petroni, et al. (1989) Haemophilus influenzae type b in respiratory secretions. Pediatr Infect Dis J 8(3), 148-151.
183. HS Zarkowsky, D Gallagher, FM Gill, et al. (1986) Bacteremia in sickle hemoglobinopathies. J Pediatr 109(4), 579-585.
184. JA Winkelstein and ER Moxon (1992) The role of complement in the host's defense against Haemophilus influenzae. J Infect Dis 165(Suppl 1), S62–S65.
185. FS Rosen and CA Janeway (1968) Diagnosis and treatment of antibody deficiency syndromes. Postgrad Med 43(5), 188-194.
186. RR Chilcote, RL Baehner and D Hammond (1976) Septicemia and meningitis in children splenectomized for Hodgkin's disease. N Engl J Med 295(15), 798-800.
187. DW Keller and RF Breiman (1995) Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Clin Infect Dis 21(Suppl 1), S77-S83.
188. A Casadevall, J Dobroszycki, C Small and LA Pirofski (1992) Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS. Am J Med 92(6), 587-590.
189. AK Takala (1994) Risk Factors in Transmission of Haemophilus influenzae type b. RW Ellis, D Granoff (Eds) Development and Clinical Uses of Haemophilus b Conjugate Vaccines New York, NY: Marcel Dekker 357-370.
190. RA Insel, M Amstey and ME Pichichero (1985) Postimmunization antibody to the Haemophilus influenzae type b capsule in breast milk. J Infect Dis 152(2), 407-408.
191. R Reid, J Croll, M Santosham, et al. (1994) Bacterial polysaccharide immune globulin. RW Ellis, DM Granoff (Eds) Development and Clinical Uses of Haemophilus b Conjugate Vaccines New York, NY: Marcel Dekker 329-338.
192. M Santosham, R Reid, DM Ambrosino, et al. (1987) Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl J Med 317(15), 923-929.
193. DH Smith, G Peter, DL Ingram, et al. (1973) Responses of children immunized with the capsular polysaccharide of Haemophilus influenzae type b. Pediatrics 52 637.
194. PH Makela, H Peltola, H Kayhty, et al. (1977) Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 136(Suppl), S43–S50.
195. H Kayhty, H Peltola and J Eskola (1988) Immunogenicity and reactogenicity of four Haemophilus influenzae type b capsular polysaccharide vaccines in Finnish 24-month-old children. Pediatr Infect Dis J 7(8), 574-577.
196. KP Ramsay, LA Popejoy, SW Jesse and I Gonzales-Torres (1989) Haemophilus B polysaccharide vaccine. Am J Dis Child 143 28.
197. JC Parke Jr, R Schneerson, JB Robbins and JJ Schlesselman (1977) Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg County, North Carolina (March 1974–March 1976). J Infect Dis 136S(Suppl), S51.
198. H Peltola, H Kayhty, A Sivonen and H Makela (1977) Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 60(5), 730-737.
199. From the Centers for Disease Control (1985) Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease. MMWR Morb Mortal Wkly Rep 34 201.
200. MT Osterholm, JH Rambeck, KE White, et al. (1988) Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. JAMA 260(10), 1423-1428.
201. ED Shapiro, TV Murphy, ER Wald and CA Brady (1988) The protective efficacy of Haemophilus b polysaccharide vaccine. JAMA 260(10), 1419-1422.
202. JB Milstien, TB Gross and JN Kuritsky (1987) Adverse reactions reported following receipt of Haemophilus influenzae type b vaccine: an analysis after 1 year of marketing. Pediatrics 80 270.
203. LH Harrison, CV Broome, AW Hightower, et al. (1988) A day care-based study of the efficacy of Haemophilus b polysaccharide vaccine. JAMA 260 1413.
204. JI Ward, CV Broome, LH Harrison, et al. (1988) Haemophilus influenzae type b vaccines: lessons for the future. Pediatrics 81(6), 886-893.
205. SB Black, HR Shinefield, RA Hiatt and BH Fireman (1988) Efficacy of Haemophilus influenzae type b capsular polysaccharide vaccine. Pediatr Infect Dis J 7 149.
206. SK Sood and RS Daum (1990) Disease caused by Haemophilus influenzae type b in the immediate period after homologous immunization: immunologic investigation. Pediatrics 85S(Suppl), 698.
207. CD Berkowitz, JI Ward, K Meier, et al. (1987) Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of age. J Pediatr 110(4), 509-514.
208. M Lepow, JS Samuelson and LK Gordon (1985) Safety and immunogenicity of H. influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age. J Pediatr 106 185-189.
209. H Kayhty, J Eskola, H Peltola, et al. (1987) Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid. J Infect Dis 155(1), 100-106.
210. S Feldman, F Gigliotti, JL Shenap, et al. (1990) Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis 114(6), 1006-1010.
211. J Eskola, H Kayhty, AK Takala, et al. (1990) A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 323(20), 1381-1387.
212. J Ward, G Brenneman, GW Letson and WL Heyward (1990) Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N Engl J Med 323(20), 1393-1401.
213. RB Turner, CO Cimino and BJ Sullivan (1991) Prospective comparison of the immune response of infants to three Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 10(2), 108-112.
214. SJ Holmes, TV Murphy, RS Anderson, et al. (1991) Immunogenicity of four Haemophilus influenzae type b conjugate vaccines in 17- to 19-month-old children. J Pediatr 118(3), 364-371.
215. MD Decker, KM Edwards, R Bradley and P Palmer (1992) Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 120(2 Pt 1), 184-189.
216. DM Granoff, EL Anderson, MT Osterholm, et al. (1992) Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 121(2), 187-194.
217. LR Bulkow, RB Wainwright, GW Letson, SJ Chang and JI Ward (1993) Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 12(6), 484-492.
218. Y Schlesinger and DM Granoff (1992) Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 267(11), 1489-1494.
219. M Santosham, J Hill, M Wolff, et al. (1991) Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population. Pediatr Infect Dis J 10(2), 113-117.
220. RS Daum, GR Siber, GA Ballanco and SK Sood (1991) Serum anticapsular antibody response in the first week after immunization of adults and infants with the Haemophilus influenzae type β- Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Infect Dis 164(6), 1154-1159.
221. MS Einhorn, GA Weinberg, EL Anderson, et al. (1986) Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet 2(8502), 299-302.
222. DM Ambrosino, SK Sood, MC Lee, et al. (1992) IgG1, IgG2 and IgM responses to two Haemophilus influenzae type b conjugate vaccines in young infants. Pediatr Infect Dis J 11(10), 855-859.
223. VI Ahonkhai, LJ Lukacs, LC Jonas, et al. (1990) Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): Clinical evaluation. Pediatrics 85(4 Pt 2), 676-681.
224. R Yogev, M Arditi, EG Chadwick, MD Amer and PA Sroka (1990) Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses. Pediatrics 85(4 Pt 2), 690-693.
225. ED Shapiro, LA Capobianco, AT Berg and MQ Zitt (1989) The immunogenicity of Hemophilus influenzae type B polysaccharide- Neisseria meningitidis group B outer membrane protein complex vaccine in infants and young children. J Infect Dis 160(6), 1064-1067.
226. GA Weinberg, MS Einhorn, AA Lenoir, et al. (1987) Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide- Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr 111(1), 22-27.
227. Ward JI, Bulkow L, Wainwright R, Chang S. Immune tolerance and lack of booster responses to Haemophilus influenzae (Hib) conjugate vaccination in infants immunized beginning at birth [abstract]. In: Programs and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1992 October 11–14, Anaheim, California.
228. S Kurikka, H Kayhty, H Peltola, et al. (1995) Neonatal immunization: response to Haemophilus influenzae type β-tetanus toxoid conjugate vaccine. Pediatrics 95(6), 815-822.
229. EV Millar, KL O'Brien, JP Watt, et al. (2005) Epidemiology of invasive Haemophilus influenzae type A disease among Navajo and White Mountain Apache children, 1988–2003. Clin Infect Dis 40(6), 823-830.
230. A Munoz, A Salvador, NL Brodsky, et al. (1995) Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine. Pediatrics 96(2 Pt 1), 216-219.
231. LK Washburn, TM O'Shea, DC Gillis, et al. (1993) Response to Haemophilus influenzae type b conjugate vaccine in chronically ill premature infants. J Pediatr 123(5), 791-794.
232. PT Heath, R Booy, J McVernon, et al. (2003) Hib vaccination in infants born prematurely. Arch Dis Child 88(3), 206-210.
233. K Kristensen, A Gyhrs, B Lausen, et al. (1996) Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J 15(6), 525-529.
234. CT D'Angio, WM Maniscalco and ME Pichichero (1995) Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics 96(1 Pt 1), 18-22.
235. EL Anderson, MD Decker, JA Englund, et al. (1995) Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA 273(11), 849-853.
236. D Scheifele, B Law, L Mitchell and J Ochnio (1996) Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Vaccine 14(15), 1399-1406.
237. R Reid, M Santosham, J Croll, et al. (1993) Antibody response of Navajo children primed with PRP-OMP vaccine to booster doses of PRP-OMP vs. HbOC vaccine. Pediatr Infect Dis J 12(10), 812-815.
238. RZ Dintzis (1994) Structure/Function Relationships in Vaccines. RW Ellis, D Granoff (Eds) Development and Clinical Uses of Haemophilus b Conjugate Vaccines New York, NY: Marcel Dekker 111-127.
239. LD Lise, D Mazier, M Jolivet, et al. (1987) Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier. Infect Immun 55(11), 2658-2661.
240. LA Herzenberg, T Tokuhisa and LA Herzenberg (1980) Carrier-priming leads to hapten-specific suppression. Nature 285(5767), 664-667.
241. DM Granoff, MH Rathore, SJ Holmes, et al. (1993) Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 1993; 11(Suppl 1), S46-S51.
242. P Anderson (1983) Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun 39(1), 233-238.
243. R Schneerson, JB Robbins, C Chu, et al. (1984) Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun 45(3), 582-591.
244. T Guimaraes, RF Cereda, PJ Bianchin, et al. (2002) Antibody response to Haemophilus influenzae type b tetanus conjugate vaccine with two doses given at 3 and 5 months of age. Int J Infect Dis 6(2), 113-117.
245. FO Castillo de, MD Decker, M Estopinan, et al. (1994) Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type β-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 13(7), 635-639.
246. T Barington, A Gyhrs, K Kristensen and C Heilmann (1994) Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun 62(1), 9-14.
247. SB Black, HR Shinefield, B Fireman, et al. (1991) Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr Infect Dis J 10(2), 97-104.
248. H Peltola, J Eskola, H Kayhty, et al. (1994) Clinical comparison of the Haemophilus influenzae type B polysaccharide-diphtheria toxoid and the oligosaccharide-CRM197 protein vaccines in infancy. Arch Pediatr Adolesc Med 148(6), 620-625.
249. M Santosham, M Wolff, R Reid, et al. (1991) The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 324(25), 1767-1772.
250. CM Vadheim, DP Greenberg, E Eriksen, et al. (1994) Eradication of Haemophilus influenzae type b disease in southern California. Kaiser-UCLA Vaccine Study Group. Arch Pediatr Adolesc Med 148(1), 51-56.
251. L Moulton, S Chung, J Croll, et al. (2000) Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol 29(4), 753-756.
252. P Horby, R Gilmour, H Wang and P McIntyre (2003) Progress towards eliminating Hib in Australia: an evaluation of Haemophilus influenzae type b prevention in Australia, 1 July 1993 to 30 June 2000. Commun Dis Intell 27(3), 324-341.
253. L Gortzak-Uzan, D Fraser and R Dagan (1998) [Epidemiology of invasive Hemophilus influenzae B infections in Bedouins and Jews; conjugate Hib vaccines]. Harefuah 135(5–6), 175-80, 256.
254. R Booy, ER Moxon, JA Macfarlane, RT Mayon-White and MP Slack (1992) Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region. Lancet 340(8823), 847.
255. R Lagos, I Horwitz, J Toro, et al. (1996) Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 15(3), 216-222.
256. B Fritzell and SA Plotkin (1992) Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 121 355-362.
257. SA Madhi, K Petersen, A Madhi, et al. (2000) Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis 31(1), 170-176.
258. D Gibb, A Giacomelli, J Masters, et al. (1996) Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. Pediatr Infect Dis J 15(12), 1097-1101.
259. MM Farley, DS Stephens, PS Brachman Jr, et al. (1992) Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med 116(10), 806-812.
260. SA Madhi, L Kuwanda, L Saarinen, et al. (2005) Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 23(48–49), 5517-5525.
261. SS De Sousa dos, MH Lopes, V Simonsen and HH Caiaffa Filho (2004) Haemophilus influenzae type b immunization in adults infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 20(5), 493-496.
262. K Chokephaibulkit, W Phongsamart, N Vanprapar, et al. (2004) Catch-up vaccination against Haemophilus influenzae type b in human immunodeficiency virus-infected Thai children older than 2 years old. Vaccine 22(15–16), 2018-2022.
263. AJ Melvin and KM Mohan (2003) Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 111(6 Pt 1), e641-e644.
264. SA Madhi, K Petersen, M Khoosal, et al. (2002) Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 21(4), 315-321.
265. GF Laube, C Berger, P Goetschel, et al. (2002) Immunization in children with chronic renal failure. Pediatr Nephrol 17(8), 638-642.
266. MS Sever, A Yildiz, H Eraksoy, et al. (1999) Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Nephron 81(1), 55-59.
267. J Storek, F Viganego, MA Dawson, et al. (2003) Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood 101(8), 3319-3324.
268. E Vance, S George, EC Guinan, et al. (1998) Comparison of multiple immunization schedules for Haemophilus influenzae type β-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant 22(8), 735-741.
269. VS Li, A Sciotto, M Fisichella, et al. (1999) Immune responses to administration of a vaccine against Haemophilus influenzae type B in splenectomized and non-splenectomized patients. J Infect 39(1), 38-41.
270. W Newcomer, M Santosham, S Bengston, et al. (1993) Immunogenicity of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer membrane protein complex conjugate vaccine in infants and children with sickle cell disease. Pediatr Infect Dis J 12(12), 1026-1027.
271. PH Makela, H Kayhty, T Leino, et al. (2003) Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 22(2), 287-292.
272. BA Claesson, B Trollfors, T Lagergard, et al. (2005) Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine. Pediatr Infect Dis J 24(5), 463-464.
273. DW Scheifele, SA Halperin, R Guasparini, et al. (1999) Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. J Pediatr 135(2 Pt 1), 240-245.
274. CL Trotter, ME Ramsay and MP Slack (2003) Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 6(1), 55-58.
275. MH Slack, D Schapira, RJ Thwaites, et al. (2004) Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. Arch Dis Child Fetal Neonatal Ed 89(3), F269-F271.
276. T Nolan, A Altmann, M Skeljo, C Streeton and L Schuerman (2004) Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine 23(1), 14-20.
277. J McVernon, NA Mitchison and ER Moxon (2004) T helper cells and efficacy of Haemophilus influenzae type b conjugate vaccination. Lancet Infect Dis 4(1), 40-43.
278. J McVernon, PD Johnson, AJ Pollard, et al. (2003) Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child 88(5), 379-383.
279. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine. Recommendations of the advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 42(RR-13), 1-15.
280. OF D'Cruz, ED Shapiro, KN Spiegelman, et al. (1989) Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barre syndrome) after immunization with Haemophilus influenzae type b conjugate vaccine. J Pediatr 115(5 Pt 1), 743-746.
281. KR Stratton, CJ Howe and RB Johnston Jr (1994) Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 271(20), 1602-1605.
282. G Tudor-Williams, J Frankland, D Isaacs, et al. (1989) Haemophilus influenzae type b conjugate vaccine trial in Oxford: Implications for the United Kingdom. Arch Dis Child 64(4), 517-519.
283. BA Claesson, B Trollfors, T Lagergard, et al. (1988) Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J Pediatr 112(5), 695-702.
284. Recommended childhood immunization schedule—United States, 1998. MMWR Morb Mortal Wkly Rep 47(1), 8-12.
285. Global Programme for Vaccines and Immunization (GPV). The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 73(10), 64-68.
286. M Santosham, JA Englund, P McInnes, et al. (2001) Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. Pediatr Infect Dis J 20(10), 931-940.
287. JA Englund, WP Glezen, C Thompson, et al. (1997) Haemophilus influenzae type β-specific antibody in infants after maternal immunization. Pediatr Infect Dis J 16(12), 1122-1130.
288. K Mulholland, RO Suara, G Siber, et al. (1996) Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. JAMA 275(15), 1182-1188.
289. PT Heath, R Booy, H Griffiths, et al. (2000) Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 31(4), 973-980.
290. M Cerquetti, R Cardines, MLC degli Atti, et al. (2005) Presence of multiple copies of the capsulation b locus in invasive Haemophilus influenzae type b (Hib) strains isolated from children with Hib conjugate vaccine failure. J Infect Dis 192 819-823.
291. H Kalies, T Verstraeten, V Grote, et al. (2004) Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/ Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/ H. influenzae type b combination vaccines in Germany. Pediatr Infect Dis J 23(10), 944-950.
292. F Fagnani, FC Le, I Durand and M Gibergy (2004) Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule. Eur J Health Econ 5(2), 143-149.
293. GS Marshall (2004) One for all: newer combination vaccines in practice. Pediatr Ann 33(8), 501-511.
294. TY Lin, YH Wang, LY Chang, et al. (2003) Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/ Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age. Chang Gung Med J 26(5), 315-322.
295. SB Black, HR Shinefield, P Ray, et al. (1993) Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diphtheria-tetanus toxoids-pertussis vaccine in infancy. The Kaiser Permanente Pediatric Vaccine Study Group. Pediatr Infect Dis J 12(12), 981-985.
296. EK Mulholland, VI Ahonkhai, AM Greenwood, et al. (1993) Safety and immunogenicity of Haemophilus influenzae type B- Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants. Pediatr Infect Dis J 12(8), 632-637.
297. C Ferreccio, J Clemens, A Avendano, et al. (1991) The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 10(10), 764-771.
298. JD Clemens, C Ferreccio, MM Levine, et al. (1992) Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA 267(5), 673-678.
299. N Watemberg, R Dagan, Y Arbelli, et al. (1991) Safety and immunogenicity of Haemophilus type β-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr Infect Dis J 10(10), 758-763.
300. CY Lee, J Thipphawong, LM Huang, et al. (1999) An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type β-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics 103(1), 25-30.
301. HJ Schmitt, F Zepp, S Muschenborn, et al. (1998) Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr 157(3), 208-214.
302. A.F.I. Botet Asensi FI, A Veronese, OM Del Carmen, et al. (2003) Immunogenicity and safety in infants of a DTwPHib full liquid vaccine. Acta Paediatr 92(5), 541-545.
303. D Goldblatt, P Richmond, E Millard, et al. (1999) The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J Infect Dis 180(2), 538-541.
304. J Eskola, RM Olander, T Hovi, et al. (1996) Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 348(9043), 1688-1692.
305. J Eskola, J Ward, R Dagan, et al. (1999) Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354(9195), 2063-2068.
306. HJ Schmitt, KR von, B Hassenpflug, et al. (2001) Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/ H. influenzae type b combination vaccines. Pediatr Infect Dis J 20(8), 767-774.
307. DJ West, GP Rabalais, B Watson, et al. (2001) Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines. BioDrugs 15(6), 413-418.
308. DP Greenberg, VK Wong, S Partridge, et al. (2000) Immunogenicity of a Haemophilus influenzae type β-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Pediatr Infect Dis J 19(12), 1135-1140.
309. ME Pichichero and S Passador (1997) Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine. Clin Infect Dis 25(6), 1378-1384.
310. F Zepp, M Knuf, U Heininger, et al. (2004) Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 22(17–18), 2226-2233.
311. J Fernandez, S Balter, J Feris, et al. (2000) Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine. Am J Trop Med Hyg 62(4), 485-490.
312. R Lagos, MT Valenzuela, OS Levine, et al. (1998) Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 351(9114), 1472-1476.
313. RE Huebner, M Nicol, R Mothupi, et al. (2004) Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine 23(6), 802-806.
314. E Tamm, A Veronese, M Contorni, et al. (2005) Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine 23(14), 1715-1719.
315. DW Scheifele (1996) Recent trends in pediatric Haemophilus influenzae type b infectios in Canada. Immunization Monitoring Program, Active (IMPACT) of the Canadian Paediatric Society and the Laboratory Centre for Disease Control. Can Med Assoc J 154 1041-1047.
316. H Peltola, T Kilpi and M Anttila (1992) Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 340(8819), 592-594.
317. S Zielen, P Ahrens and D Hofmann (1994) Efficacy of Hib vaccine. Lancet 344 828.
318. O Garpenholt, SA Silfverdal, S Hugosson, et al. (1996) The impact of Haemophilus influenzae type b vaccination in Sweden. Scand J Infect Dis 28(2), 165-169.
319. Impact of Uruguay's introduction of the Haemophilus influenzae type b (Hib) vaccine. EPI Newsl 18(6), 6.
320. G Gallo, MLC degli Atti, M Cerquetti, et al. (2002) Impact of a regional Hib vaccination programme in Italy. Vaccine 20 993-995.
321. DG Perdue, LR Bulkow, BG Gellin, et al. (2000) Invasive Haemophilus influenzae disease in Alaskan residents aged 10 years and older before and after infant vaccination programs. JAMA 283(23), 3089-3094.
322. From the Centers for Disease Control and Prevention (2002) Progress toward eliminating Haemophilus influenzae type b disease among infants and children – United States, 1998–2000. MMWR Morb Mortal Wkly Rep 51(11), 234-237.
323. EV Millar, KL O'Brien, OS Levine, et al. (2000) Toward elimination of Haemophilus influenzae type B carriage and disease among high-risk American Indian children. Am J Public Health 90(10), 1550-1554.
324. M Gratten, F Morey, J Hanna, et al. (1994) Type, frequency and distribution of Haemophilus influenzae in central Australian aboriginal children with invasive disease. Med J Aust 160(11), 728-729.
325. MP Slack, HJ Azzopardi, RM Hargreaves and ME Ramsay (1998) Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Pediatr Infect Dis J 17(9 Suppl), S204-S207.
326. PT Heath, R Booy, HJ Azzopardi, et al. (2001) Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatr Infect Dis J 20(3), 300-305.
327. O'Brien KL, Bronsdon MA, Carlone GM, et al. Effect of a 7-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal (NP) Carriage Among Navajo and White Mountain Apache (N/WMA) Infants [abstract]. In: Pediatric Academic Societies’ 2001 Annual Meeting; 2001 April 28-May 1; Baltimore, MD.
328. MH Kyaw, R Lynfield, W Schaffner, et al. (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354(14), 1455-1463.
329. WP Hanage, K Auranen, R Syrjanen, et al. (2004) Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines. Infect Immun 72(1), 76-81.
330. M Lipsitch (1999) Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 5(3), 336-345.
331. V Mitchell, D Walker, P Zuber, et al. (2005) Evidence-based decision making about Hib vaccination. Lancet 365(9463), 936-937.
332. DR Feikin, CB Nelson, JP Watt, et al. (2004) Rapid assessment tool for Haemophilus influenzae type b disease in developing countries. Emerg Infect Dis 10(7), 1270-1276.
333. M Hotomi, Y Ikeda, M Suzumoto, et al. (2005) A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Vaccine 23(10), 1294-1300.
334. JM Kyd, AW Cripps, LA Novotny and LO Bakaletz (2003) Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx. Infect Immun 71(8), 4691-4699.
335. GM Bertot, PD Becker, CA Guzman and S Grinstein (2004) Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis 189(7), 1304-1312.
336. AR Foxwell, AW Cripps and KB Dear (2003) Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev (3), CD001958.
337. XX Gu, SF Rudy, C Chu, et al. (2003) Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae. Vaccine 21(17–18), 2107-2114.
338. An Effectiveness Trial of Hib Vaccine in Bangladesh (2004) Reported by Public Health Sciences Division, ICDDR, B. Health and Science Bulletin 2(3), 11-13.